Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-4-15
pubmed:abstractText
The relevance of the melanocortin system to sexual activity is well established, and nonselective peptide agonists of the melanocortin receptors have shown evidence of efficacy in human sexual dysfunction. The role of the MC4 receptor subtype has received particular scrutiny, but the sufficiency of its selective activation in potentiating sexual response has remained uncertain owing to conflicting data from studies in preclinical species. We describe here the discovery of a novel series of small-molecule MC4 receptor agonists derived from library hit 2. The addition of methyl substituents at C3 and C5 of the 4-phenylpiperidin-4-ol ring was found to be markedly potency-enhancing, enabling the combination of low nanomolar potencies with full rule-of-five compliance. In general, the series shows only micromolar activity at other melanocortin receptors. Our preferred compound 40a provided significant systemic exposure in humans on both sublingual and oral administration and was safe and well tolerated up to the maximum tested dose. In a pilot clinical study of male erectile dysfunction, the highest dose of 40a tested (200 mg) provided a similar level of efficacy to sildenafil.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1520-4804
pubmed:author
pubmed-author:AdamsCathrynC, pubmed-author:BlaggJulianJ, pubmed-author:BrownAlan DAD, pubmed-author:BrownT BruceTB, pubmed-author:BurringDenise JDJ, pubmed-author:CalabreseAndrewA, pubmed-author:ColeSusanS, pubmed-author:EdmundsNickN, pubmed-author:FeederNeilN, pubmed-author:FradetDavidD, pubmed-author:GaboardiSamanthaS, pubmed-author:GillonValV, pubmed-author:HaughieScottS, pubmed-author:HeatheringtonAnneA, pubmed-author:HepworthDavidD, pubmed-author:LansdellMark IMI, pubmed-author:LewisMarkM, pubmed-author:MartinSteven WSW, pubmed-author:MistryNeelaN, pubmed-author:MountNatalieN, pubmed-author:Neal-MorganStevieS, pubmed-author:PhippsJoanneJ, pubmed-author:QuintonFayeF, pubmed-author:RUSSJJ, pubmed-author:StaceyPeterP, pubmed-author:SudworthMariaM, pubmed-author:SultanaStefanS, pubmed-author:TweedySarahS, pubmed-author:VerrierHughH, pubmed-author:WaymanChrisC, pubmed-author:WilsonPeterP
pubmed:issnType
Electronic
pubmed:day
22
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3183-97
pubmed:meshHeading
pubmed-meshheading:20329799-Administration, Intranasal, pubmed-meshheading:20329799-Administration, Oral, pubmed-meshheading:20329799-Administration, Sublingual, pubmed-meshheading:20329799-Animals, pubmed-meshheading:20329799-Biological Availability, pubmed-meshheading:20329799-Clinical Trials, Phase I as Topic, pubmed-meshheading:20329799-Crystallography, X-Ray, pubmed-meshheading:20329799-Dogs, pubmed-meshheading:20329799-Erectile Dysfunction, pubmed-meshheading:20329799-Hepatocytes, pubmed-meshheading:20329799-Humans, pubmed-meshheading:20329799-Male, pubmed-meshheading:20329799-Microsomes, Liver, pubmed-meshheading:20329799-Models, Molecular, pubmed-meshheading:20329799-Piperidines, pubmed-meshheading:20329799-Pyrrolidines, pubmed-meshheading:20329799-Randomized Controlled Trials as Topic, pubmed-meshheading:20329799-Rats, pubmed-meshheading:20329799-Receptor, Melanocortin, Type 4, pubmed-meshheading:20329799-Stereoisomerism, pubmed-meshheading:20329799-Structure-Activity Relationship
pubmed:year
2010
pubmed:articleTitle
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.
pubmed:affiliation
Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT139NJ, U.K. mark.i.lansdell@googlemail.com
pubmed:publicationType
Journal Article, In Vitro